Market Place
Sourcing Support
Robbins LLP Alerts Investors to ImmunityBio Action Lawsuit
27 Mar 2026 //
PHARMIWEB
ImmunityBio Confirms NMIBC Trial Power, BLA 2026
26 Mar 2026 //
PHARMIWEB
Immunitybio Hit With FDA Warning Letter Over Anktiva Promotions
24 Mar 2026 //
FIERCE PHARMA
ANKTIVA Approved In Macau For BCG-Unresponsive NMIBC CIS
20 Mar 2026 //
PHARMIWEB
ANKTIVA Approved In Macau For BCG-Unresponsive NMIBC Tumors
20 Mar 2026 //
PHARMIWEB
Immunitybio Announces NCCN Clinical Practice Guidelines
17 Mar 2026 //
BUSSINESSWIRE
ImmunityBio Achieve Milestone with Large-Scale NK Cell Production
13 Mar 2026 //
PHARMIWEB
ImmunityBio Resubmits ANKTIVA BLA to FDA After Review
09 Mar 2026 //
PR NEWSWIRE
Immunitybio To Review FY 2025 Financial Results On March 3, 2026
27 Feb 2026 //
PHARMIWEB
ImmunityBio Finishes Enrollment In Key Trial For ANKTIVA Combo
26 Feb 2026 //
PHARMIWEB
ImmunityBio: 700% YoY ANKTIVA Growth in Lung Cancer
23 Feb 2026 //
BUSINESSWIRE
ImmunityBio Founder to Speak at Cancer 2035 Summit
23 Feb 2026 //
BUSINESSWIRE
ImmunityBio Receives Authorization from European for ANKTIVA
18 Feb 2026 //
BUSINESSWIRE
ImmunityBio Reports Productive Meeting With Saudi FDA
17 Feb 2026 //
BUSINESSWIRE
ImmunityBio Launches ANKTIVA Phase 2 Trial in Indolent Lymphomas
02 Feb 2026 //
PHARMIWEB
ImmunityBio: OS Servival Not Reached in GBM with ANKTIVA CAR-NK
23 Jan 2026 //
BUSINESSWIRE
Immunitybio Progresses FDA Talks For ANKTIVA
20 Jan 2026 //
PHARMIWEB
Immunitybio Touts 15-Month Complete Response In CAR-NK Trial
16 Jan 2026 //
FIERCE BIOTECH
ImmunityBio Advances NMIBC Program on ANKTIVA Data
16 Jan 2026 //
PHARMIWEB
Functional Force Platforms to Disrupt Tumors by 2026
16 Jan 2026 //
PR NEWSWIRE
Immunitybio Shows 700% Year-Over-Year Growth, Generates $113M
15 Jan 2026 //
BUSINESSWIRE
Saudi FDA Accelerates Approval Of Immunitybio`s ANKTIVA
14 Jan 2026 //
BUSINESSWIRE
Saudi FDA Accelerates Approval For Immunitybio`s ANKTIVA Combo
14 Jan 2026 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA Pairs with Checkpoint Inhibitors for NSCLC
13 Jan 2026 //
PHARMIWEB
Nantworks, Immunitybio Launch U.S.-Saudi Biotech Alliance Summit
12 Jan 2026 //
PHARMIWEB
ImmunityBio`s Soon-Shiong Joins 2025 Top 100 Oncology Influencers
29 Dec 2025 //
BUSINESSWIRE
96% 3-Year Survival with ANKTIVA/BCG in BCG-Unresponsive NMIBC
16 Dec 2025 //
BUSINESSWIRE
ImmunityBio Receives CMA Recommendation For Anktiva
12 Dec 2025 //
PHARMIWEB
Survey Finds NMIBC Patients Want More Care Conversations
13 Nov 2025 //
BUSINESSWIRE
ANKTIVA® Boosts Survival in Non-Small Cell Lung Cancer Patients
08 Sep 2025 //
PHARMAWEB
ImmunityBio Anktiva + NK Cells, Optune Gio Show 100% DCR in GBM
26 Aug 2025 //
BUSINESSWIRE
ImmunityBio Starts Ph 2 Of ANKTIVA In Patients With Long COVID
19 Aug 2025 //
BUSINESSWIRE
ImmunityBio CD19 CAR-NK Shows Responses in Lymphoma Trial
13 Aug 2025 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA® Administered to Bladder Cancer Patients
11 Aug 2025 //
BUSINESSWIRE
ImmunityBio Q2 Earnings Show 60% Revenue Rise, $43M YTD Sales
05 Aug 2025 //
BUSINESSWIRE
ImmunityBio Posts 60% Revenue Jump in Q2 2025
25 Jul 2025 //
BUSINESSWIRE
ImmunityBio Secures $80M from Institutional Investors
25 Jul 2025 //
BUSINESSWIRE
UK MHRA Nod for ImmunityBio`s ANKTIVA Plus BCG for Bladder Cancer
07 Jul 2025 //
BUSINESSWIRE
ASCO Report: Treatment of Lymphopenia Benefits Pancreatic Cancer
03 Jun 2025 //
BUSINESSWIRE
Immunity Bio Gets FDA Authorization for Anktiva in Lymphopenia
02 Jun 2025 //
BUSINESSWIRE
ImmunityBio, Saudi Arabia Launch Cancer BioShield MOU
27 May 2025 //
BUSINESSWIRE
ImmunityBio Doubles Net Revenue and Grows 150% in Q1 2025
12 May 2025 //
BUSINESSWIRE
ImmunityBio Urgent Meeting FDA Change Guidance Jan 2025 NMIBC sBL
05 May 2025 //
BUSINESSWIRE
Ankitva + BCG Shows 80% NMIBC Response at 36 Months
28 Apr 2025 //
BUSINESSWIRE
J&J puts ImmunityBio on defense mode in bladder cancer
27 Apr 2025 //
FIERCE PHARMA
ImmunityBio to Present Cancer Advances at AU Meeting
21 Apr 2025 //
BUSINESSWIRE
ImmunityBio Submits Supplemental BLA for NMIBC Papillary Disease
15 Apr 2025 //
BUSINESSWIRE
ImmunityBio Hosts Meeting on Clinical Programs and ANKTIVA Launch
07 Apr 2025 //
BUSINESSWIRE
ImmunityBio to Host Investor Day
26 Mar 2025 //
BUSINESSWIRE
ImmunityBio Begins Dosing Recombinant BCG in US, 60 Sites Launching
13 Mar 2025 //
BUSINESSWIRE
ImmunityBio Sees Sales Growth After J9028 Code Issuance
03 Mar 2025 //
BUSINESSWIRE
ImmunityBio Gets FDA RMAT For ANKTIVA & CAR-NK In Pancreatic Cancer
27 Feb 2025 //
BUSINESSWIRE
ImmunityBio, SII win FDA nod to help combat BCG shortage
21 Feb 2025 //
FIERCE PHARMA
FDA OKs ImmunityBio rBCG To Ease TICE BCG Shortage
19 Feb 2025 //
BUSINESSWIRE
ImmunityBio Receives MHRA Acceptance for Ankitva® in Bladder Cancer
13 Feb 2025 //
BUSINESSWIRE
ImmunityBio, BeiGene Collaborate On Phase 3 Lung Cancer Trial
29 Jan 2025 //
BUSINESSWIRE
ImmunityBio’s Anktiva MAA Accept for BCG-Unresponsive Bladder Cancer
27 Jan 2025 //
BUSINESSWIRE
Global Expansion Plans Set For Anktiva Cancer Treatment
15 Jan 2025 //
BUSINESSWIRE
ImmunityBio Updates Progress On FDA Regulatory Submissions
15 Jan 2025 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA® J-Code (J9028) Now Permanently Effective
06 Jan 2025 //
BUSINESSWIRE
